Sanofi India Limited

Sanofi India Limited

Sanofi India Limited has announced its financial results for the quarter ended June 30, 2026, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, and profits before tax and exceptional items increased 19% to INR 112 crores.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the change in Senior Management Personnel, specifically the cessation of Mr. Nakul Verma as Public Affairs & Market Access-Head, effective July 31st, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the schedule of an investor/analysts call for an update on unaudited financial results for the quarter and half year ended 30th June 2026.

Sanofi India Limited

Sanofi India Limited has announced the resignation of Mr. Rachid Ayari as Whole Time Director and Chief Financial Officer, effective September 30, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has announced the resignation of Mr. Rachid Ayari as Chief Financial Officer, effective September 30, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the change in management, with Mr. Rachid Ayari stepping down as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel on September 30, 2026, to transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has informed the Exchange regarding Change in Director(s) of the company. Mr. Rachid Ayari will step down as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel on 30th September 2026 to transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has received a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026, confirming the dematerialization of securities and listing on stock exchanges.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a favourable order issued by the Income Tax Department- Office of the Commissioner of Income tax Appeal - 49, Mumbai, dropping the proceedings initiated under Section 201 of the Income-tax Act, 1961, for Assessment Year 2019-20.

Sanofi India Limited

Sanofi India Limited has informed the Exchange regarding the closure of its trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter and half year ending 30th June 2026.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding an order issued by Deputy Commissioner, State GST, Ahmedabad, Gujarat, rejecting the company's refund application for the period 2014-15 to 2017-18.